Photo of Meredith  ErvinePhoto of Meredith  Ervine

Meredith  Ervine



Maurice A. Deane School of Law at Hofstra University, J.D.
  • summa cum laude
  • Hofstra Law Review, Senior Notes and Comments Editor
University of Michigan, B.A.
  • Economics and Program in the Environment
  • with high distinction

Prior Employment

  • Pillsbury Winthrop Shaw Pittman LLP, Senior Associate, 2008-2015

Bar Admissions

Professional Affiliations

American Bar Association

  • Business Law, Member

State Bar of Michigan

News & Resources


Ms. Ervine is a corporate attorney focusing her practice on Securities and Corporate Governance matters. She has experience representing clients across many industries on securities issues, mergers and acquisitions and general corporate matters. 

  • Advises clients regarding compliance with the securities laws, including the reporting requirements of the SEC and the national securities exchanges
  • Assists clients in connection with annual and special shareholder meetings, including preparation of proxy statements
  • Counsels clients in public and private offerings of both debt and equity securities
  • Advises clients on corporate governance best practices
  • Counsels clients on transactional matters, including corporate finance and mergers and acquisitions
  • Assists clients with general contract and planning matters


Representative Clients

  • Represents a Midwest-based medical device company listed on Nasdaq
  • Represents a Midwest-based clinical-stage biopharmaceutical company listed on Nasdaq
  • Serves as special or secondary counsel to three Northeast-based unaffiliated controlled companies (wholesale/retail fashion, wholesale/retail consumer goods and manufacturer of advanced materials) listed on the NYSE
  • Advised a Northeast-based plastic packaging films manufacturer listed on Nasdaq

Recent Transactions

  • Co-lead counsel on $785 million sale of plastic packaging films manufacturer (Nasdaq) through merger to an NYSE-listed company
  • $65 million common stock rights offering and backstop commitment (NYSE) for leading contemporary fashion brand (represented the independent directors)
  • $30 million initial public offering of common stock (Nasdaq) for a clinical-stage biopharmaceutical company
  • Registered direct offerings of preferred stock and warrants for a Nasdaq-listed medical device company

News & Resources